anti braf antibody Search Results


anti-braf polyclonal antibody  (TargetMol)
N/A
   Buy from Supplier
braf antibody  (Boster Bio)
92
Boster Bio braf antibody
Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( <t>BRAF</t> <t>,</t> <t>ARID2</t> , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.
Braf Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+braf+antibody/Anti-BRAF+V600E+Antibody/pmc10680082-146-4-11
Average 92 stars, based on 1 article reviews
braf antibody - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
anti phospho b raf  (St Johns Laboratory)
88
St Johns Laboratory anti phospho b raf
Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( <t>BRAF</t> <t>,</t> <t>ARID2</t> , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.
Anti Phospho B Raf, supplied by St Johns Laboratory, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+braf+antibody/Anti-Phospho-BRAF-S445+Antibody/pmc05821345-58-49-52
Average 88 stars, based on 1 article reviews
anti phospho b raf - by Bioz Stars, 2026-10
88/100 stars
  Buy from Supplier
rabbit monoclonal anti c raf  (Boster Bio)
90
Boster Bio rabbit monoclonal anti c raf
Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( <t>BRAF</t> <t>,</t> <t>ARID2</t> , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.
Rabbit Monoclonal Anti C Raf, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+braf+antibody/Anti-B+Raf+Rabbit+Monoclonal+Antibody/pmc07930933-82-51-58
Average 90 stars, based on 1 article reviews
rabbit monoclonal anti c raf - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti-b-raf (v600e) mouse monoclonal antibody  (NewEast Biosciences)
90
NewEast Biosciences anti-b-raf (v600e) mouse monoclonal antibody
Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( <t>BRAF</t> <t>,</t> <t>ARID2</t> , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.
Anti B Raf (V600e) Mouse Monoclonal Antibody, supplied by NewEast Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+braf+antibody/mouse+anti+braf+v600e+antibody/pmc11112369__mmc3-132-4-10
Average 90 stars, based on 1 article reviews
anti-b-raf (v600e) mouse monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti-braf v600e (ve1) mouse monoclonal antibody  (OptiView Technologies)
90
OptiView Technologies anti-braf v600e (ve1) mouse monoclonal antibody
Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( <t>BRAF</t> <t>,</t> <t>ARID2</t> , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.
Anti Braf V600e (Ve1) Mouse Monoclonal Antibody, supplied by OptiView Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+braf+antibody/anti+braf+v600e++ve1++antibody/pm30479181-307-11-18
Average 90 stars, based on 1 article reviews
anti-braf v600e (ve1) mouse monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
b raf antibody st john  (St Johns Laboratory)
91
St Johns Laboratory b raf antibody st john
Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( <t>BRAF</t> <t>,</t> <t>ARID2</t> , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.
B Raf Antibody St John, supplied by St Johns Laboratory, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+braf+antibody/Anti-BRAF+Antibody/10__1515_slash_tjb___2023___0072-109-8-10
Average 91 stars, based on 1 article reviews
b raf antibody st john - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
anti-brafv600e ihc600  (GenomeMe Inc)
90
GenomeMe Inc anti-brafv600e ihc600
Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( <t>BRAF</t> <t>,</t> <t>ARID2</t> , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.
Anti Brafv600e Ihc600, supplied by GenomeMe Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+braf+antibody/anti+braf+v600e+antibody+ihc600/pm39240343-23923-16-21
Average 90 stars, based on 1 article reviews
anti-brafv600e ihc600 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti-braf monoclonal antibody  (NewEast Biosciences)
90
NewEast Biosciences anti-braf monoclonal antibody
Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( <t>BRAF</t> <t>,</t> <t>ARID2</t> , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.
Anti Braf Monoclonal Antibody, supplied by NewEast Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+braf+antibody/anti+braf+monoclonal+antibody/pm27363650-74-19-22
Average 90 stars, based on 1 article reviews
anti-braf monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
recombinant human anti-human braf antibody fab fragment  (Creative BioMart)
N/A
Recombinant Human Antibody Fab Fragment recognizes and reacts with Human BRAF, expressed in HEK 293 cells.Products can be used for: Enzyme-linked Immunosorbent Assay; Western blot; Neutralization; Functional StudyStore at -20°C. Avoid multiple freeze/thaw cycles.http://www.creativebiolabs.net/Recombinant-Human-Anti-human-BRAF-Antibody-Fab-Fragment-14909.htm
   Buy from Supplier
anti-phospho-braf (thr401) polyclonal antibody  (TargetMol)
N/A
   Buy from Supplier
anti-phospho-braf-s728 antibody  (St Johns Laboratory)
N/A
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in
   Buy from Supplier

Image Search Results


Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( BRAF , ARID2 , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.

Journal: Frontiers in Oncology

Article Title: Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer

doi: 10.3389/fonc.2023.1285508

Figure Lengend Snippet: Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of PFS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for PFS between three genes( BRAF , ARID2 , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. (F, G) Kaplan-Meier plots of PFS for CRC patients undergoing exclusive first-line chemotherapy (F) and chemotherapy combined with bevacizumab (G) , stratified by BRAF mutation status. PFS, progression-free survival; MT, mutation type; WT, wiled type.

Article Snippet: Staining was performed with BRAF antibody (Bioss, Beijing, China), ARID2 antibody (Boster, CA, USA), and AR (Bioss, Beijing, China) to demonstrate protein expression, respectively.

Techniques: Mutagenesis

Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of OS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for OS between three genes( BRAF , ARID2 , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. OS, overall survival; MT, mutation type; WT, wiled type.

Journal: Frontiers in Oncology

Article Title: Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer

doi: 10.3389/fonc.2023.1285508

Figure Lengend Snippet: Prognostic associated somatic mutated genes in FPHYP CRC cohort. (A) Univariable analyses of OS concerning somatic gene mutations in FPHYP CRC tumors. (B) Kaplan-Meier curves for OS between three genes( BRAF , ARID2 , and KMT2C ) combined MT and WT groups. (C–E) Kaplan-Meier curves for PFS based on BRAF (C) , ARID2 (D) , and KMT2C (E) mutation status. OS, overall survival; MT, mutation type; WT, wiled type.

Article Snippet: Staining was performed with BRAF antibody (Bioss, Beijing, China), ARID2 antibody (Boster, CA, USA), and AR (Bioss, Beijing, China) to demonstrate protein expression, respectively.

Techniques: Mutagenesis

Construction of a four-gene mutation signature prediction disease progression and prognosis in FPHYP cohort. (A, B) Univariate and multivariate analyses were performed to assess the impact of clinicopathological features, individual somatic gene mutations, and the four-gene mutation signature on PFS (A) and OS (B) in CRC. (C) The Kaplan-Meier survival analysis for PFS in CRC patients between the four-gene combined MT and WT groups based on BRAF , ARID2 , KMT2C , and GNAQ mutation status. (D) The Kaplan-Meier survival analysis for OS in CRC cases between the four-gene combined MT and WT groups based on BRAF , ARID2 , KMT2C , and GNAQ mutation status. (E, F) ROC curves for PFS (E) and OS (F) that dependent on time were generated to evaluate the prognostic model’s performance, which is based on the gene mutation status within the FPHYP cohort. PFS, progression-free survival; OS, overall survival; MT, mutation type; WT, wiled type; ROC, receiver operating characteristic.

Journal: Frontiers in Oncology

Article Title: Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer

doi: 10.3389/fonc.2023.1285508

Figure Lengend Snippet: Construction of a four-gene mutation signature prediction disease progression and prognosis in FPHYP cohort. (A, B) Univariate and multivariate analyses were performed to assess the impact of clinicopathological features, individual somatic gene mutations, and the four-gene mutation signature on PFS (A) and OS (B) in CRC. (C) The Kaplan-Meier survival analysis for PFS in CRC patients between the four-gene combined MT and WT groups based on BRAF , ARID2 , KMT2C , and GNAQ mutation status. (D) The Kaplan-Meier survival analysis for OS in CRC cases between the four-gene combined MT and WT groups based on BRAF , ARID2 , KMT2C , and GNAQ mutation status. (E, F) ROC curves for PFS (E) and OS (F) that dependent on time were generated to evaluate the prognostic model’s performance, which is based on the gene mutation status within the FPHYP cohort. PFS, progression-free survival; OS, overall survival; MT, mutation type; WT, wiled type; ROC, receiver operating characteristic.

Article Snippet: Staining was performed with BRAF antibody (Bioss, Beijing, China), ARID2 antibody (Boster, CA, USA), and AR (Bioss, Beijing, China) to demonstrate protein expression, respectively.

Techniques: Mutagenesis, Biomarker Discovery, Generated

Immunohistochemical analysis of BRAF and ARID2 in CRC. (A, B) The BRAF expression original field was acquired from tissue sections (magnification, 200x) of the BRAF -MT (A) and BRAF -WT (B) groups. (C) Comparison of the IOD/Area value between BRAF -MT and BRAF -WT groups. (D, E) The BRAF expression original field was acquired from tissue sections (magnification, 200x) of stage I (D) and stage IV (E) groups. (F) Comparison of the IOD/Area value between stage I and IV groups. (G, H) The ARID2 expression original field was acquired from tissue sections (magnification, 200x) of the ARID2 -MT (G) and ARID2 -WT (H) groups. (I) Comparison of the IOD/Area value between ARID2 -MT and ARID2 -WT groups. (J, K) The ARID2 expression original field was acquired from tissue sections (magnification, 200x) of stage I (J) and stage IV (K) groups. (L) Comparison of the IOD/Area value between stage I and IV groups. MT, mutation type; WT, wiled type; IOD, cumulative optical density.

Journal: Frontiers in Oncology

Article Title: Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer

doi: 10.3389/fonc.2023.1285508

Figure Lengend Snippet: Immunohistochemical analysis of BRAF and ARID2 in CRC. (A, B) The BRAF expression original field was acquired from tissue sections (magnification, 200x) of the BRAF -MT (A) and BRAF -WT (B) groups. (C) Comparison of the IOD/Area value between BRAF -MT and BRAF -WT groups. (D, E) The BRAF expression original field was acquired from tissue sections (magnification, 200x) of stage I (D) and stage IV (E) groups. (F) Comparison of the IOD/Area value between stage I and IV groups. (G, H) The ARID2 expression original field was acquired from tissue sections (magnification, 200x) of the ARID2 -MT (G) and ARID2 -WT (H) groups. (I) Comparison of the IOD/Area value between ARID2 -MT and ARID2 -WT groups. (J, K) The ARID2 expression original field was acquired from tissue sections (magnification, 200x) of stage I (J) and stage IV (K) groups. (L) Comparison of the IOD/Area value between stage I and IV groups. MT, mutation type; WT, wiled type; IOD, cumulative optical density.

Article Snippet: Staining was performed with BRAF antibody (Bioss, Beijing, China), ARID2 antibody (Boster, CA, USA), and AR (Bioss, Beijing, China) to demonstrate protein expression, respectively.

Techniques: Immunohistochemical staining, Expressing, Comparison, Mutagenesis